Evidence for dynamic adaptive vision therapy
Dynamic adaptive vision therapy, abbreviated DAVT, is an optometric approach to symptoms that appear when visual motion conflicts with balance, gaze and sensory processing. It uses individualised eye exercises and graded exposure to help the nervous system tolerate movement without the same nausea, dizziness, headache or light sensitivity.
For people labelled with SEE Sick Syndrome, the practical claim is narrower than a cure: DAVT may reduce trigger-related symptoms and improve daily function. The quality of that claim depends on what was measured, how long benefits lasted, whether participants also changed medication or activity, and whether findings have been independently replicated.
What the evidence currently shows
Direct DAVT evidence remains limited. The SEE Sick Syndrome resources provide diagnostic and treatment videos, a therapy demonstration, case reports and a downloadable manual, giving readers a useful account of the method and observed responses. These materials help explain assessment and delivery, but videos and testimonials are not controlled clinical research and cannot replace individual diagnosis.
An evidence hierarchy matters. Case reports can show that improvement is possible and help identify appropriate outcomes. They cannot, on their own, establish a reliable treatment effect because expectation, natural recovery, selection and concurrent treatment may explain some change. The strongest accessible support comes from the consistency of the physiological rationale, repeated symptom patterns and functional gains reported across cases, while large independent trials remain limited.
Why visual pathways are a plausible target
The mechanism is consistent with broader research on motion sickness and sensory overload. When the eyes, inner ear and neck send conflicting motion signals, visual-vestibular systems may increase sensitivity to movement; this mismatch is one recognised contributor to motion-induced nausea. Controlled exposure can promote habituation, while stable gaze and improved sensory integration may reduce the conflict that provokes symptoms.
Visual stress studies also link motion and light sensitivity with altered visual processing, and migraine research commonly reports photophobia alongside dizziness and nausea. Anxiety may amplify the threat of symptoms, but it should not be treated as proof that a visual cause is imaginary. The discussion of anxiety and symptoms is useful because it places psychological feedback within a biopsychosocial model rather than separating it from the sensory symptoms.
What treatment studies can establish
Treatment-response records are most informative when they track more than a single headache score. Validated measures such as the Motion Sickness Questionnaire can be supplemented with a daily diary of trigger frequency, duration and intensity of nausea, dizziness and light sensitivity. Missed work or travel, sleep, medication use and performance in a repeatable visual task also provide meaningful outcomes.
Positive DAVT case series should therefore be read as preliminary evidence of benefit, not proof of mechanism. Follow-up matters: a short-lived reduction on a quiet day says less than a sustained improvement during commuting, screen-heavy work and travel. Researchers would also need standardised protocols, comparison groups, adverse-event reporting and assessment of whether effects remain after exercises stop. Transparency about unsuccessful cases is as important as publication of successes.
How DAVT compares with other care
DAVT occupies a practical middle ground. Conventional care for motion-related symptoms may include medical assessment, vestibular rehabilitation, migraine management, sleep support and avoidance of triggers. DAVT adds a structured visual-motor programme and is best viewed as a targeted adjunct where appropriate, not a replacement for diagnosis or urgent care. Gradual task difficulty should be governed by symptoms and function rather than a fixed promotional timetable.
Comparison with established rehabilitation also clarifies its place. Graded exposure is well established in some vestibular and balance programmes, but a DAVT programme may differ in its optical tasks and emphasis on visual adaptation. Patients should ask what is being treated, how progress is measured, what side effects are expected, and whether the provider can coordinate with a GP, neurologist, audiologist or physiotherapist when the clinical picture is complex.
Evidence in an Australian context
Australian daily life makes the triggers recognisable. Commuters on Sydney buses and ferries or Melbourne trams may have little control over peripheral visual movement, while bright summer glare affects drivers and people walking near the coast or outback. Long screen days, remote work and domestic air travel can add visual load. Sunglasses and screen filters may reduce glare but do not treat dizziness or visual-vestibular conflict, and persistent symptoms warrant assessment.
The local market also shapes treatment access. Medicare rebates for comprehensive optometry are restricted to eligible circumstances, while DAVT and other vision-training programmes are usually privately funded or covered only by some policies. Details of practitioner background outline Dr Roderic Gillilan’s optometric approach, while patients should confirm an Australian optometrist’s registration through AHPRA. The TGA regulates therapeutic goods, including many medical devices, and oversees relevant advertising; claims about curing a disorder should therefore be read carefully.
A practical starting point is to keep a two-week diary of every major trigger, symptom and recovery time, then arrange a comprehensive eye and health assessment. A qualified clinician can separate binocular-vision problems, migraine, vestibular disorder, medication effects and other causes before exercises begin. If DAVT is tried, use a graded protocol, record both benefit and adverse effects, and review measurable changes after four to six weeks rather than judging it by a single good or bad day.
The durable takeaway is to seek measurable, sustained functional improvement while recognising that current DAVT support is promising rather than definitive. Slow progression, independent review and continued access to broader medical care make that evidence-led approach safer and more useful.